Harue Tada
About
Harue Tada is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology.
According to data from OpenAlex, Harue Tada has authored 55 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 15 papers in Surgery and 12 papers in Oncology. Recurrent topics in Harue Tada's work include Lung Cancer Treatments and Mutations (9 papers), Electromagnetic Fields and Biological Effects (5 papers) and Wound Healing and Treatments (5 papers). Harue Tada is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Electromagnetic Fields and Biological Effects (5 papers) and Wound Healing and Treatments (5 papers). Harue Tada collaborates with scholars based in Japan, Australia and Singapore. Harue Tada's co-authors include Satoshi Teramukai, Masanori Fukushima, Hiroshi Sasaki, Kenichi Yoshimura, Takashi Akamizu, Akira Shimizu, Taiga Irako, Masataka Yokode, Akiko Matsuyama and Hiroshi Hosoda and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Harue Tada
52 papers receiving 1.2k citations
Peers
Harue Tada
Mark A. Bach United States
Alessandro Pini Italy
Robert S. Bienkowski United States
Zhigang He China
Jason Gandhi United States
Haitao Zhang China
Bing Chen China
David Zangen Israel
Magdalena Woźniak Poland
Takahiro Suzuki Japan
Citations per year, relative to Harue Tada Harue Tada (= 1×)
peers
Mark A. Bach
Countries citing papers authored by Harue Tada
Since
Specialization
Citations
This map shows the geographic impact of Harue Tada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Harue Tada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Harue Tada more than expected).
Fields of papers citing papers by Harue Tada
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Harue Tada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Harue Tada. The network helps show where Harue Tada may publish in the future.
Co-authorship network of co-authors of Harue Tada
This figure shows the co-authorship network connecting the top 25 collaborators of Harue Tada. A scholar is included among the top collaborators of Harue Tada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Harue Tada. Harue Tada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Ohashi, Shinya, et al.. (2025). Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial. EClinicalMedicine. 91. 103689–103689.
2.
Muto, Manabu, Katsuyuki Sakanaka, Shinya Ohashi, et al.. (2024). Effect of nivolumab combined with definitive chemoradiotherapy on response rate for esophageal cancer: An immune active intrinsic subtype could be its biomarker—The NOBEL trial.. Journal of Clinical Oncology. 42(16_suppl). 4068–4068.
3.
Ikeda, Hanako Ohashi, Tomoko Hasegawa, Takayuki Nakagawa, et al.. (2024). Efficacy and Safety of Branched Chain Amino Acids on Retinitis Pigmentosa: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Translational Vision Science & Technology. 13(8). 29–29.
4.
Yamanaka, Hiroki, Takashi Nakano, Tatsuya Ito, et al.. (2023). A high-hydrostatic pressure device for nevus tissue inactivation and dermal regeneration for reconstructing skin defects after giant congenital melanocytic nevus excision: a clinical trial. Regenerative Therapy. 24. 167–173.
5.
Muto, Manabu, Keiko Minashi, Tomonori Yano, et al.. (2023). Expression molecular subtype as a predictor of outcomes of chemoradiotherapy for esophageal cancer.. Journal of Clinical Oncology. 41(16_suppl). 4030–4030.
6.
Mori, Yukiko, Osamu Kikuchi, Takahiro Horimatsu, et al.. (2022). Multicenter phase II study of trifluridine/tipiracil for esophageal squamous carcinoma refractory/intolerant to 5-fluorouracil, platinum compounds, and taxanes: the ECTAS study. Esophagus. 19(3). 444–451.
7.
Nomura, Takashi, Eriko Sumi, Gyohei Egawa, et al.. (2021). Safety and Efficacy of FIT039 for Verruca Vulgaris: A Placebo-Controlled, Phase I/II Randomized Controlled Trial. SHILAP Revista de lepidopterología. 1(3). 100026–100026.
8.
Ikeda, Hanako Ohashi, Yuki Muraoka, Masayuki Hata, et al.. (2020). Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial. PLoS ONE. 15(2). e0229068–e0229068.
9.
Nomura, Takashi, Eriko Sumi, Gyohei Egawa, et al.. (2019). The efficacy of a cyclin dependent kinase 9 (CDK9) inhibitor, FIT039, on verruca vulgaris: study protocol for a randomized controlled trial. Trials. 20(1). 489–489.
10.
Sumi, Eriko, Takashi Nomura, Ryuji Uozumi, et al.. (2018). Safety and Plasma Concentrations of a Cyclin-dependent Kinase 9 (CDK9) Inhibitor, FIT039, Administered by a Single Adhesive Skin Patch Applied on Normal Skin and Cutaneous Warts. Clinical Drug Investigation. 39(1). 55–61.
11.
Kojima, Takashi, Haruo Kasai, Takahiro Tsushima, et al.. (2017). A phase II study of TAS-102 for advanced/recurrent esophageal cancer refractory/intolerable to standard therapies. Annals of Oncology. 28. v218–v218.
12.
Aoyama, Tomoki, Koji Goto, Ryosuke Kakinoki, et al.. (2014). An Exploratory Clinical Trial for Idiopathic Osteonecrosis of Femoral Head by Cultured Autologous Multipotent Mesenchymal Stromal Cells Augmented with Vascularized Bone Grafts. Tissue Engineering Part B Reviews. 20(4). 233–242.
13.
Morimoto, Naoki, Kenichi Yoshimura, Miyuki Niimi, et al.. (2013). Novel Collagen/Gelatin Scaffold with Sustained Release of Basic Fibroblast Growth Factor: Clinical Trial for Chronic Skin Ulcers. Tissue Engineering Part A. 19(17-18). 1931–1940.
14.
Morimoto, Naoki, Tatsuya Ito, Satoru Takemoto, et al.. (2012). An exploratory clinical study on the safety and efficacy of an autologous fibroblast‐seeded artificial skin cultured with animal product‐free medium in patients with diabetic foot ulcers. International Wound Journal. 11(2). 183–189.
15.
Kawahara, Masaaki, Harue Tada, Akihiro Tokoro, et al.. (2011). Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01). BMC Cancer. 11(1). 356–356.
16.
Yoshimura, Koji, Toshiyuki Kamoto, Osamu Ogawa, et al.. (2010). Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: An open‐label study. International Journal of Urology. 17(6). 548–554.
17.
Hirami, Yasuhiko, Michiko Mandai, Masayo Takahashi, et al.. (2009). Association of clinical characteristics with disease subtypes, initial visual acuity, and visual prognosis in neovascular age-related macular degeneration. Japanese Journal of Ophthalmology. 53(4). 396–407.
18.
Kamihira, Osamu, Ryohei Hattori, Akito Yamaguchi, et al.. (2009). Laparoscopic Radical Nephroureterectomy: A Multicenter Analysis in Japan. European Urology. 55(6). 1397–1409.
19.
Yamamoto, Keiichi, Shigemi Matsumoto, Harue Tada, et al.. (2007). Development of Data Capture System for Clinical Study by the Secondary Use of Electronic Health Records. 2212.
20.
Nishimura, Tsutomu, et al.. (2006). Lessons from gefitinib-induced interstitial lung disease in Japan: Problems in approval, pharmacovigilance, and regulatory decision-making procedures. Pharmacy Practice. 4(4). 168–78.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Mark A. Bach Breakdown of academic impact, for papers by Alessandro Pini Breakdown of academic impact, for papers by Robert S. Bienkowski Breakdown of academic impact, for papers by Zhigang He Breakdown of academic impact, for papers by Jason Gandhi Breakdown of academic impact, for papers by Haitao Zhang Breakdown of academic impact, for papers by Bing Chen Breakdown of academic impact, for papers by David Zangen Breakdown of academic impact, for papers by Magdalena Woźniak Breakdown of academic impact, for papers by Takahiro Suzuki